CTSO CytoSorbents Corporation: שולי רווח תפעולי

Cytosorbents minimizes risks by developing blood purification systems for intensive care units. The current operating margin illustrates this efficiency, where -26.70 characterizes this valuation parameter. Profit stability is based on a global distribution network across Europe and the US. The defensive qualities of the business and demographic factors insulate financial results from market downturns.
CytoSorbents Corp - פילוחים אנליטיים ומדדי מפתח (CTSO)

The effective commercialization of blood filtration systems in the US and EU directly correlates with the operating profit spread, calculated as the ratio of operating profit to revenue. This chart allows for an assessment of Cytosorbents (CTSO) management's ability to transform revenues into net operating cash flow before financial obligations, confirming the stability of the market capitalization through the fundamental efficiency of the business model.